Vertex has raised its full-year 2026 revenue guidance after third-quarter sales climbed 12%, but the Crinetics acquisition sharply increased costs and debt. The next major test arrives on 30 November, when US regulators are due to rule on povetacicept for IgA nephropathy.
- Third-quarter revenue rose 12% to US$3.44 billion
- Full-year revenue guidance lifted to US$13.15 billion-US$13.25 billion
- GAAP net income fell to US$653.6 million after Crinetics-related costs
- CASGEVY revenue nearly sextupled year on year to US$99.2 million
- Povetacicept faces a US FDA action date on 30 November
Revenue growth lifts Vertex’s 2026 target
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) raised its full-year revenue guidance after third-quarter sales increased 12% to US$3.44 billion. The new target of US$13.15 billion to US$13.25 billion is only a modest lift from the previous range, but it points to continued momentum beyond the company’s long-established cystic fibrosis franchise.
Newer medicines begin to carry more weight
Cystic fibrosis products still generated US$3.27 billion in the quarter, with ALYFTREK revenue reaching US$705.8 million compared with US$247 million a year earlier. Growth was also visible in the newer portfolio: CASGEVY revenue rose to US$99.2 million from US$16.9 million, while JOURNAVX reached US$58.3 million from US$19.6 million. Vertex said more than 750,000 JOURNAVX prescriptions were filled during the quarter, although the product remains early in its commercial ramp.
Crinetics deal weighs on reported earnings
The headline earnings picture was less clean. GAAP net income fell to US$653.6 million from US$1.08 billion, primarily because of expenses tied to the Crinetics Pharmaceuticals acquisition, which closed on 1 September for an equity value of about US$10 billion. Vertex recorded approximately US$500 million in acquisition-related compensation and transaction costs during the quarter, meaning non-GAAP net income of US$1.21 billion was broadly unchanged from a year earlier.
The acquisition has also altered Vertex’s financial profile. Cash, cash equivalents and marketable securities stood at US$9.8 billion at 30 September, down from US$12.3 billion at the end of 2025, after US$9 billion of net cash was used for the Crinetics transaction and share repurchases. A US$4.5 billion term loan partly funded that outlay, while full-year combined GAAP research, acquired in-process research and development, and selling expenses guidance rose to US$7.15 billion-US$7.2 billion.
Povetacicept becomes the immediate regulatory test
Vertex’s most immediate pipeline catalyst is povetacicept, which is under priority review by the US Food and Drug Administration for accelerated approval in IgA nephropathy. The assigned action date is 30 November 2026. If approved, the medicine would give Vertex its first commercial product in nephrology, while the company is also testing it in primary membranous nephropathy and generalised myasthenia gravis. The outcome remains subject to the regulator’s review and the evidence supporting the application.
The pipeline now has several expensive proving grounds
Beyond the Crinetics assets, Vertex says it has completed enrolment in the interim-analysis cohort of its pivotal AMPLITUDE study of inaxaplin in APOL1-mediated kidney disease and remains on track to report data in early 2027. It expects to complete enrolment in Phase 3 diabetic peripheral neuropathy studies of suzetrigine by the end of 2026, advance VX-017 for type 1 diabetes into pivotal development in 2027, and complete enrolment in the adult atumelnant trial for congenital adrenal hyperplasia in the first quarter of 2027. Those milestones offer potential breadth, but they also leave the company carrying a larger commercial and development cost base while the new franchises establish themselves.
Bottom Line?
Vertex has bought itself a broader growth story, but the next phase depends on whether new medicines can scale quickly enough to justify higher spending, acquisition debt and the premium paid for Crinetics.
Questions in the middle?
- Will povetacicept receive approval on or before the 30 November FDA action date?
- Can PALSONIFY, CASGEVY and JOURNAVX deliver enough growth to offset the higher post-acquisition expense base?
- How quickly can Vertex reduce the financial drag from Crinetics integration and its new term loan?